IQVIA Holdings Inc. $IQV Shares Sold by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 98.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,055 shares of the medical research company’s stock after selling 192,110 shares during the period. Vaughan Nelson Investment Management L.P.’s holdings in IQVIA were worth $521,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA in the fourth quarter worth $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA in the fourth quarter worth about $27,000. Gilpin Wealth Management LLC bought a new position in IQVIA in the 4th quarter valued at about $27,000. CrossGen Wealth LLC bought a new position in IQVIA in the 4th quarter valued at about $28,000. Finally, Measured Wealth Private Client Group LLC acquired a new position in IQVIA during the 3rd quarter valued at about $30,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $167.83 on Tuesday. The firm’s 50 day moving average is $173.60 and its 200-day moving average is $191.01. The stock has a market capitalization of $28.01 billion, a P/E ratio of 20.80, a P/E/G ratio of 1.44 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its board has authorized a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on IQV shares. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a report on Friday, March 6th. Royal Bank Of Canada started coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price for the company. Evercore reiterated an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Finally, Mizuho set a $215.00 price objective on IQVIA in a research note on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.